Patients with Bcl-xL positive GBM (score 1 and 2) showed a median progression of 136 days and median survival of 280 days against median progression of 284.5 days and survival of 611 days of patients with Bcl-xL negative lesions. This evidence concerns the gene BCL2L1 and glioblastoma.